Payment overview · 2025
General Payments
$31,203.58
255 reported records · 26 companies
Healthcare provider profile · identity verified
Lori H Travis, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PHOENIX, AZ · NPI 1093794885
Verified facts
What the public records show
CMS Open Payments records show Lori H Travis, MD received $31,203.58 in general payments during 2025 across 255 reported records.
Mallinckrodt Hospital Products Inc. accounted for 67.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ampyra, Bafiertam, Nurtec Odt, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rytary by this doctor in 2024.
Cycle Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Bafiertam as an associated drug or biological on 1343 records involving 850 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Bafiertam by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ampyra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21,066.51 | 67.5% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,272.55 | 10.5% | 11 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2,628.97 | 8.4% | 15 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $830.75 | 2.7% | 45 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $411.05 | 1.3% | 19 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $378.62 | 1.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $361.95 | 1.2% | 25 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $270.74 | 0.9% | 11 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $266.77 | 0.8% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $266.01 | 0.8% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $202.03 | 0.7% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $183.65 | 0.6% | 12 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $179.18 | 0.6% | 12 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $171.21 | 0.6% | 12 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $140.00 | 0.5% | 12 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.04 | 0.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $73.77 | 0.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.17 | 0.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.17 | 0.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.96 | 0.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.03 | 0.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $45.75 | 0.1% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $41.97 | 0.1% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $32.14 | 0.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.32 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.27 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,360.00 | 4 |
| Food and Beverage | $5,471.07 | 241 |
| Consulting Fee | $4,775.00 | 2 |
| Travel and Lodging | $2,234.81 | 3 |
| Education | $362.70 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21,066.51 | 21 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $3,272.55 | 11 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $2,628.97 | 15 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $592.65 | 31 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $411.05 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $343.80 | 23 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $289.97 | 21 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $266.77 | 10 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $196.83 | 14 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $183.65 | 12 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $179.18 | 12 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $171.21 | 12 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $153.76 | 10 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $140.00 | 12 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $124.04 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $113.10 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $112.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $73.77 | 4 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $70.03 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $57.17 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $53.17 | 3 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $52.29 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $51.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.03 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.03 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $45.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AMPYRA ampyra |
2025 | Ampyra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Bafiertam bafiertam |
2025 | Bafiertam | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Cycle Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Bafiertam open payments reported associated product |
CMS Open Payments — General Payments 1343 supporting records · 850 recipient NPIs · example record 1248898758 |
Bafiertam · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 86 | 22 |
| Baclofen | Baclofen | 70 | 18 |
| Levetiracetam | Levetiracetam | 67 | 15 |
| Aubagio | Teriflunomide | 39 | suppressed |
| Teriflunomide | Teriflunomide | 36 | suppressed |
| Primidone | Primidone | 34 | 13 |
| Memantine Hcl | Memantine Hcl | 32 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Armodafinil | Armodafinil | 31 | suppressed |
| Bafiertam | Monomethyl Fumarate | 28 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 28 | suppressed |
| Copaxone | Glatiramer Acetate | 26 | suppressed |
| Dalfampridine Er | Dalfampridine | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Kesimpta Pen | Ofatumumab | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Ampyra | Dalfampridine | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Glatopa | Glatiramer Acetate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31,203.58 · 255 records | Mallinckrodt Hospital Products Inc. | ACTHAR, AJOVY, AMPYRA, BRIUMVI, Bafiertam, Briviact, CREXONT, HYQVIA, KESIMPTA, Leqembi, NURTEC ODT, Ocrevus Zunovo, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, SKYCLARYS, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ampyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error